Tags

Type your tag names separated by a space and hit enter

Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg.
Eur Respir J. 2005 Jun; 25(6):1001-10.ER

Abstract

This is the first prospective clinical trial in which patients with acute bacterial exacerbation of chronic bronchitis have been stratified by degree of underlying illness. Uncomplicated patients were randomised to levofloxacin 750 mg once daily (q.d.) for 3 days or azithromycin q.d. for 5 days. Complicated patients were randomised to levofloxacin 750 mg q.d. for 5 days or amoxicillin 875 mg/clavulanate 125 mg twice daily for 10 days. Regardless of therapy, complicated patients demonstrated lower clinical and microbiological success than uncomplicated patients. Clinical success for clinically evaluable patients was similar for levofloxacin and azithromycin (93.0 versus 90.1%, respectively), and levofloxacin and amoxicillin/clavulanate (79.2 versus 81.7%, respectively). For microbiologically evaluable patients, clinical response to levofloxacin for 3 days was superior to azithromycin for 5 days (96.3 versus 87.4%, respectively), and levofloxacin for 5 days was similar to amoxicillin/clavulanate for 10 days (81.4 versus 80.9%, respectively). Microbiological eradication was superior for levofloxacin for 3 days compared with azithromycin for 5 days (93.8 versus 82.8%, respectively), and similar for levofloxacin and amoxicillin/clavulanate for 10 days (81.4 versus 79.8%, respectively). In conclusion, levofloxacin 750 mg for 3 days was comparable to azithromycin for 5 days for uncomplicated patients with acute bacterial exacerbation of chronic bronchitis, while 5 days of 750 mg levofloxacin was comparable to 10 days of amoxicillin/clavulanate for complicated acute bacterial exacerbation of chronic bronchitis.

Authors+Show Affiliations

The University of Michigan Health System, 1500 East Medical Center Drive, 3916 Taubman Center, Box 0360, Ann Arbor, MI 48109, USA. fmartine@umich.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15929954

Citation

Martinez, F J., et al. "Patient Stratification in the Management of Acute Bacterial Exacerbation of Chronic Bronchitis: the Role of Levofloxacin 750 Mg." The European Respiratory Journal, vol. 25, no. 6, 2005, pp. 1001-10.
Martinez FJ, Grossman RF, Zadeikis N, et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J. 2005;25(6):1001-10.
Martinez, F. J., Grossman, R. F., Zadeikis, N., Fisher, A. C., Walker, K., Ambruzs, M. E., & Tennenberg, A. M. (2005). Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. The European Respiratory Journal, 25(6), 1001-10.
Martinez FJ, et al. Patient Stratification in the Management of Acute Bacterial Exacerbation of Chronic Bronchitis: the Role of Levofloxacin 750 Mg. Eur Respir J. 2005;25(6):1001-10. PubMed PMID: 15929954.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. AU - Martinez,F J, AU - Grossman,R F, AU - Zadeikis,N, AU - Fisher,A C, AU - Walker,K, AU - Ambruzs,M E, AU - Tennenberg,A M, PY - 2005/6/3/pubmed PY - 2005/9/28/medline PY - 2005/6/3/entrez SP - 1001 EP - 10 JF - The European respiratory journal JO - Eur Respir J VL - 25 IS - 6 N2 - This is the first prospective clinical trial in which patients with acute bacterial exacerbation of chronic bronchitis have been stratified by degree of underlying illness. Uncomplicated patients were randomised to levofloxacin 750 mg once daily (q.d.) for 3 days or azithromycin q.d. for 5 days. Complicated patients were randomised to levofloxacin 750 mg q.d. for 5 days or amoxicillin 875 mg/clavulanate 125 mg twice daily for 10 days. Regardless of therapy, complicated patients demonstrated lower clinical and microbiological success than uncomplicated patients. Clinical success for clinically evaluable patients was similar for levofloxacin and azithromycin (93.0 versus 90.1%, respectively), and levofloxacin and amoxicillin/clavulanate (79.2 versus 81.7%, respectively). For microbiologically evaluable patients, clinical response to levofloxacin for 3 days was superior to azithromycin for 5 days (96.3 versus 87.4%, respectively), and levofloxacin for 5 days was similar to amoxicillin/clavulanate for 10 days (81.4 versus 80.9%, respectively). Microbiological eradication was superior for levofloxacin for 3 days compared with azithromycin for 5 days (93.8 versus 82.8%, respectively), and similar for levofloxacin and amoxicillin/clavulanate for 10 days (81.4 versus 79.8%, respectively). In conclusion, levofloxacin 750 mg for 3 days was comparable to azithromycin for 5 days for uncomplicated patients with acute bacterial exacerbation of chronic bronchitis, while 5 days of 750 mg levofloxacin was comparable to 10 days of amoxicillin/clavulanate for complicated acute bacterial exacerbation of chronic bronchitis. SN - 0903-1936 UR - https://www.unboundmedicine.com/medline/citation/15929954/Patient_stratification_in_the_management_of_acute_bacterial_exacerbation_of_chronic_bronchitis:_the_role_of_levofloxacin_750_mg_ L2 - http://erj.ersjournals.com/cgi/pmidlookup?view=long&pmid=15929954 DB - PRIME DP - Unbound Medicine ER -